# Liraglutide

## Saxenda inj 18mg/3mL

| TAH Drug Code      | [ISAX](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ISAX)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Adjunct to reduced-calorie diet & increased physical activity for chronic weight management in adult patients with initial BMI of ?30 kg/m2 or ?27 kg/m2 to <30 kg/m2 in the presence of at least 1 weight-related comorbidity eg, dysglycaemia (pre-diabetes or type 2 DM), HTN, dyslipidaemia.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Dosing             | Obesity, Or overweight in the presence of at least one weight-related comorbidity: Initial, 0.6 mg once daily for 1 week; increase weekly in increments of 0.6 mg/day until maintenance dosage of 3 mg once daily is reached. Evaluate weight loss after 12 weeks and discontinue use if at least 5% of body weight has not been lost.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Hypersensitivity to liraglutide or any component of the product. Personal or family history of medullary thyroid carcinoma. Personal of family history of multiple endocrine neoplasia syndrome type 2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Adverse Effects    | Common Endocrine metabolic: Hypoglycemia (Adult, monotherapy, 7.1% to 12.6%; adult, combination therapy, 3.6% to 28.2% ; pediatric, 15.2 to 21.2% ) Gastrointestinal: Constipation (Type 2 diabetes, 5% to 9.9%; weight management, 4.8% to 19.4% ), Decrease in appetite (9% to 10% ), Diarrhea (10% to 22.4% ), Indigestion (4% to 9.6% ), Nausea (Type 2 diabetes, 18% to 28.4% ; weight management, 39.3% to 42.4% ), Vomiting (Type 2 Diabetes, 6% to 15.7% ; weight management, 34.4% (pediatric) ) Neurologic: Headache (9.1% to 13.6% ) Respiratory: Upper respiratory infection (6% to 9.5% ) Serious Endocrine metabolic: Breast cancer (0.6% ), C-cell hyperplasia of thyroid, Medullary thyroid carcinoma, Papillary thyroid carcinoma (0.2% ) Gastrointestinal: Cholecystitis (0.8% ), Cholelithiasis (1.15 to 2.2% ), Colorectal cancer (0.2% ), Pancreatic cancer, Pancreatitis (0.3% to 0.8% ) Immunologic: Anaphylaxis Psychiatric: Suicidal, completed (Pediatric, 0.8% ), Suicidal thoughts (0.3% ) Renal: Acute renal failure Other: Angioedema, Breast cancer (0.7% ), Pancreatic cancer |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

